PRINCETON, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today reaffirmed the Company's guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune® HPV plus pembrolizumab for first-line treatment of recurrent and/or metastatic (R/M) HPV16-positive head and neck squamous cell cancer (HNSCC) in the first quarter of ...

文章核心观点 临床阶段生物技术公司Indaptus Therapeutics获加拿大卫生部临床试验授权，将其美国进行中的INDP - D101临床试验扩展至加拿大站点，还计划提交修正案纳入与百济神州PD - 1抑制剂的联合试验，有望加速收集临床数据，推动癌症治疗进展 [1] 公司动态 - 公司获加拿大卫生部临床试验授权，可将进行中的美国临床试验INDP - D101扩展至加拿大站点，按当前方案招募患者，还计划提交修正案纳入与百济神州PD - 1抑制剂tislelizumab的联合试验 [1] - 公司CEO称将加拿大研究人员和患者纳入临床工作可创建更多样、强大的数据集，首席医学官表示增加加拿大试验点能加速收集有价值临床数据，增强试验基础设施以加速了解Decoy20治疗潜力、优化给药方案和改善治疗结果 [2] 公司介绍 - 公司基于免疫疗法一个多世纪的进展发展而来，其创新方法基于多靶点激活免疫系统信号假设，专利技术由减毒和灭活的非致病性革兰氏阴性细菌单菌株组成，产生多激动剂Decoy平台 [3] - 公司候选产品设计为降低静脉毒性，保留激活先天和适应性免疫细胞及途径能力，在临床前模型中对多种癌症和病毒感染有单药或联合治疗活性，还能产生免疫记忆并使肿瘤炎症特征从“冷”转“热” [3] - 临床前非临床毒理学研究显示静脉给药不会持续诱导细胞因子释放综合征标志性生物标志物，可能因靶向肝脏、脾脏和肿瘤并快速清除候选产品 [3]

Fourth Quarter 2024 Highlights Revenue of $3.9 billion, a decrease of 1.3% as organic growth declined 0.5%; Organic growth of 0.4% turned positive excluding Product Line Simplification (PLS) reduction of 0.9%Record operating margin of 26.2%, an increase of 140 bps as enterprise initiatives contributed 120 bpsOperating cash flow of $1.1B; record free cash flow of $1B, an increase of 10% with a conversion of 133%GAAP EPS of $2.54, an increase of 7% 2024 Highlights Revenue of $15.9 billion, a decrease of 1.3% ...

Company doubles number of shipments in less than 20 monthsNORTH CANTON, Ohio, Feb. 5, 2025 /PRNewswire/ -- Diebold Nixdorf (NYSE: DBD), a world leader in transforming the way people bank and shop, recently celebrated the milestone of shipping more than 200,000 DN Series® ATMs from its global manufacturing plants. Diebold Nixdorf reached the 100,000-shipment milestone during the first quarter of 2023. Since then, shipments have doubled. DN Series was designed for always-on availability and provides consu ...

Receives multiple Best in KLAS awards in Claims Management & Clearinghouse and Patient Access LEHI, Utah and LOUISVILLE, Ky., Feb. 5, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced its top ranking in multiple 2025 Best in KLAS categories: Claims Management & Clearinghouse and Patient Access. Based on independent client feedback, these recognitions underscore the value healthcare providers gain from Waystar's AI-powered software pl ...

GRAND CAYMAN, Cayman Islands, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Oxbridge Re Holdings Limited (Nasdaq: OXBR) ("Oxbridge Re"), together with its subsidiary SurancePlus, is engaged in the tokenization of Real-World Assets ("RWAs"), initially with tokenized reinsurance securities, and in providing reinsurance solutions to property and casualty insurers in the Gulf Coast region of the United States, today announced it has selected Coinbase Prime to facilitate its investments in other digital assets as part of it ...

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD. "The launch of our highly anticipated AD study is a significant milestone in advancing bunt ...

HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Systemic Bio™, a 3D Systems company (NYSE: DDD), has been named the winner of the prestigious SLAS 2025 Innovation Award. This award recognizes groundbreaking technological advancements poised to drive innovation in laboratory science and automation. The competition featured cutting-edge developments led by distinguished experts from top institutions worldwide. The award highlights Systemic Bio’s proprietary h-VIOS™ platform, designed to accelerate drug discovery a ...

Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development (“R&D”) collaborations aligned with Orchestra BioMed’s partnership-enabled business model Mr. Cleary previously served as Senior Vice President (“SVP”) of Corporate Development at Medtronic plc (NYSE: MDT) (“Medtronic”), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation (“AVIM”) thera ...

-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later -- -- VAX-31 is Designed to Cover Approximately 94% of Invasive Pneumococcal Disease and Approximately 93% of Acute Otitis Media in U.S. Children Under Five -- -- Company Remains ...